Connection

Michael Gold to Female

This is a "connection" page, showing publications Michael Gold has written about Female.
Connection Strength

3.181
  1. Association of interventricular activation delay with clinical outcomes in cardiac resynchronization therapy. Heart Rhythm. 2023 Mar; 20(3):385-392.
    View in: PubMed
    Score: 0.044
  2. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.041
  3. Impact of age on catheter ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2021 04; 32(4):1077-1084.
    View in: PubMed
    Score: 0.039
  4. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
    View in: PubMed
    Score: 0.038
  5. The ECG Belt for CRT response trial: Design and clinical protocol. Pacing Clin Electrophysiol. 2020 10; 43(10):1063-1071.
    View in: PubMed
    Score: 0.038
  6. 1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The?Subcutaneous?ICD?Post?Approval Study. JACC Clin Electrophysiol. 2020 11; 6(12):1537-1550.
    View in: PubMed
    Score: 0.038
  7. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008631.
    View in: PubMed
    Score: 0.038
  8. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
    View in: PubMed
    Score: 0.037
  9. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
    View in: PubMed
    Score: 0.037
  10. Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm. 2020 04; 17(4):615-620.
    View in: PubMed
    Score: 0.036
  11. The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
    View in: PubMed
    Score: 0.036
  12. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
    View in: PubMed
    Score: 0.035
  13. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
    View in: PubMed
    Score: 0.033
  14. Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. Heart Rhythm. 2018 10; 15(10):1525-1532.
    View in: PubMed
    Score: 0.032
  15. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
    View in: PubMed
    Score: 0.032
  16. The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
    View in: PubMed
    Score: 0.031
  17. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
    View in: PubMed
    Score: 0.030
  18. Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
    View in: PubMed
    Score: 0.030
  19. The Impact of the PR Interval in Patients?Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2017 08; 3(8):818-826.
    View in: PubMed
    Score: 0.030
  20. The Rap1-cofilin-1 pathway coordinates actin reorganization and MTOC polarization at the B cell immune synapse. J Cell Sci. 2017 03 15; 130(6):1094-1109.
    View in: PubMed
    Score: 0.030
  21. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.029
  22. Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
    View in: PubMed
    Score: 0.029
  23. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9.
    View in: PubMed
    Score: 0.029
  24. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.028
  25. Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. Heart Rhythm. 2016 08; 13(8):1631-5.
    View in: PubMed
    Score: 0.028
  26. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
    View in: PubMed
    Score: 0.028
  27. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
    View in: PubMed
    Score: 0.027
  28. Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. J Am Coll Cardiol. 2015 Jun 23; 65(24):2581-2588.
    View in: PubMed
    Score: 0.026
  29. Are leadless pacemakers a niche or the future of device therapy? J Am Coll Cardiol. 2015 Apr 21; 65(15):1505-8.
    View in: PubMed
    Score: 0.026
  30. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.025
  31. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014 Aug; 11(8):1352-8.
    View in: PubMed
    Score: 0.024
  32. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
    View in: PubMed
    Score: 0.024
  33. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.024
  34. How many transvenous coils are optimal for defibrillators: one, two, or none? Heart Rhythm. 2013 Jul; 10(7):977-8.
    View in: PubMed
    Score: 0.023
  35. Influence of intracardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf trial. Circ Arrhythm Electrophysiol. 2013 Apr; 6(2):272-8.
    View in: PubMed
    Score: 0.023
  36. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
    View in: PubMed
    Score: 0.023
  37. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity. 2013 Feb; 46(1):62-73.
    View in: PubMed
    Score: 0.022
  38. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013 Apr 15; 111(8):1165-8.
    View in: PubMed
    Score: 0.022
  39. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.022
  40. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.022
  41. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.022
  42. Hemoglobin spectroscopy to evaluate hemodynamic function during tachycardias: the future of ICD discrimination algorithms? Heart Rhythm. 2012 Oct; 9(10):1592-3.
    View in: PubMed
    Score: 0.021
  43. Interactions between a left ventricular assist device and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2012 Sep; 35(9):e272-3.
    View in: PubMed
    Score: 0.021
  44. Acute performance of a right ventricular automatic pacing threshold algorithm for implantable defibrillators. Pacing Clin Electrophysiol. 2012 Mar; 35(3):259-68.
    View in: PubMed
    Score: 0.021
  45. Pre-discharge defibrillation testing: clinically important or obsolete? Europace. 2012 Feb; 14(2):155-6.
    View in: PubMed
    Score: 0.021
  46. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):359-66.
    View in: PubMed
    Score: 0.021
  47. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
    View in: PubMed
    Score: 0.020
  48. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.020
  49. Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
    View in: PubMed
    Score: 0.020
  50. Safety and efficacy of low-fluence, high-repetition rate versus high-fluence, low-repetition rate 810-nm diode laser for permanent hair removal--a split-face comparison study. J Cosmet Laser Ther. 2011 Aug; 13(4):134-7.
    View in: PubMed
    Score: 0.020
  51. Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul; 8(7):1008-13.
    View in: PubMed
    Score: 0.020
  52. A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
    View in: PubMed
    Score: 0.019
  53. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
    View in: PubMed
    Score: 0.019
  54. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
    View in: PubMed
    Score: 0.019
  55. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
    View in: PubMed
    Score: 0.019
  56. Response to Coceani: Has CRT earned a class I recommendation? Circ Heart Fail. 2010 Jul; 3(4):559-60.
    View in: PubMed
    Score: 0.019
  57. Alcohol consumption and the risk of sudden cardiac death in women: an evaluation from the Nurses' Health Study. Heart Rhythm. 2010 Oct; 7(10):1381-2.
    View in: PubMed
    Score: 0.019
  58. Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm. 2010 Nov; 7(11):1561-6.
    View in: PubMed
    Score: 0.019
  59. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009 Nov 01; 183(9):5673-84.
    View in: PubMed
    Score: 0.018
  60. Role of transesophageal echocardiography among patients with atrial fibrillation undergoing electrophysiology testing. Am J Cardiol. 2009 Nov 01; 104(9):1256-8.
    View in: PubMed
    Score: 0.018
  61. Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009 Aug; 20(8):894-900.
    View in: PubMed
    Score: 0.017
  62. Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
    View in: PubMed
    Score: 0.017
  63. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
    View in: PubMed
    Score: 0.017
  64. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
    View in: PubMed
    Score: 0.017
  65. Impact of atrial prevention pacing on atrial fibrillation burden: primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm. 2009 Mar; 6(3):295-301.
    View in: PubMed
    Score: 0.017
  66. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.017
  67. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm. 2008 Mar; 5(3):394-9.
    View in: PubMed
    Score: 0.016
  68. Atrial overdrive pacing and incidence of heart failure-related adverse events in permanently paced patients. J Interv Card Electrophysiol. 2007 Jun; 19(1):55-60.
    View in: PubMed
    Score: 0.015
  69. Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol. 2007 Jul 15; 100(2):243-6.
    View in: PubMed
    Score: 0.015
  70. Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
    View in: PubMed
    Score: 0.015
  71. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
    View in: PubMed
    Score: 0.015
  72. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
    View in: PubMed
    Score: 0.015
  73. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. J Cardiovasc Electrophysiol. 2006 Jun; 17(6):617-20.
    View in: PubMed
    Score: 0.014
  74. Coronary sinus electrode does not reduce atrial defibrillation thresholds. Heart Rhythm. 2006 Jun; 3(6):647-52.
    View in: PubMed
    Score: 0.014
  75. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
    View in: PubMed
    Score: 0.013
  76. Improved defibrillation efficacy with an ascending ramp waveform in humans. Heart Rhythm. 2005 Apr; 2(4):388-94.
    View in: PubMed
    Score: 0.013
  77. Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. Heart Rhythm. 2005 Jan; 2(1):49-54.
    View in: PubMed
    Score: 0.013
  78. Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
    View in: PubMed
    Score: 0.012
  79. The influence of gender on arrhythmias. Cardiol Rev. 2004 Mar-Apr; 12(2):97-105.
    View in: PubMed
    Score: 0.012
  80. Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. Clin Cardiol. 2004 Mar; 27(3):151-3.
    View in: PubMed
    Score: 0.012
  81. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol. 2004 Feb; 27(2):218-20.
    View in: PubMed
    Score: 0.012
  82. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
    View in: PubMed
    Score: 0.012
  83. Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. J Interv Card Electrophysiol. 2003 Dec; 9(3):391-6.
    View in: PubMed
    Score: 0.012
  84. Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol. 2003 Oct; 14(10):1036-40.
    View in: PubMed
    Score: 0.012
  85. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023 Mar 13; 14(1):1394.
    View in: PubMed
    Score: 0.011
  86. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
    View in: PubMed
    Score: 0.011
  87. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 2003 Jan; 26(1P2):483-6.
    View in: PubMed
    Score: 0.011
  88. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.011
  89. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation. 2002 Apr 30; 105(17):2043-8.
    View in: PubMed
    Score: 0.011
  90. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.011
  91. Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 2002 Apr; 13(4):332-5.
    View in: PubMed
    Score: 0.011
  92. Effect of shock polarity on the efficacy of transthoracic atrial defibrillation. Am Heart J. 2002 Mar; 143(3):541-5.
    View in: PubMed
    Score: 0.011
  93. Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
    View in: PubMed
    Score: 0.010
  94. Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. Am J Cardiol. 2001 Dec 01; 88(11):1308-11.
    View in: PubMed
    Score: 0.010
  95. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol. 2001 Nov 01; 88(9):1043-5.
    View in: PubMed
    Score: 0.010
  96. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
    View in: PubMed
    Score: 0.010
  97. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol. 2022 Jan; 23(1):93-104.
    View in: PubMed
    Score: 0.010
  98. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. Circulation. 2021 11 09; 144(19):1543-1552.
    View in: PubMed
    Score: 0.010
  99. Effects of single-dose L-theanine on motor cortex excitability. Clin Neurophysiol. 2021 09; 132(9):2062-2064.
    View in: PubMed
    Score: 0.010
  100. Contrast-enhanced image-guided lead deployment for left bundle branch pacing. Heart Rhythm. 2021 08; 18(8):1318-1325.
    View in: PubMed
    Score: 0.010
  101. Relationship of paced left bundle branch pacing morphology with anatomic location and physiological outcomes. Heart Rhythm. 2021 06; 18(6):946-953.
    View in: PubMed
    Score: 0.010
  102. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.010
  103. Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
    View in: PubMed
    Score: 0.010
  104. Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. Pacing Clin Electrophysiol. 2001 Jan; 24(1):70-4.
    View in: PubMed
    Score: 0.010
  105. Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Can J Cardiol. 2021 05; 37(5):803-809.
    View in: PubMed
    Score: 0.010
  106. Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
    View in: PubMed
    Score: 0.010
  107. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. J Drugs Dermatol. 2020 10 01; 19(10):985-991.
    View in: PubMed
    Score: 0.010
  108. Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008370.
    View in: PubMed
    Score: 0.009
  109. Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Fail. 2020 10; 7(5):2972-2982.
    View in: PubMed
    Score: 0.009
  110. Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e008267.
    View in: PubMed
    Score: 0.009
  111. Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
    View in: PubMed
    Score: 0.009
  112. Developmental outcomes following vaccine-proximate febrile seizures in children. Neurology. 2020 07 21; 95(3):e226-e238.
    View in: PubMed
    Score: 0.009
  113. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000 May 01; 85(9):1106-9.
    View in: PubMed
    Score: 0.009
  114. Characterization of Upper Gastrointestinal Motility in Infants With Persistent Distress and Non-IgE-mediated Cow's Milk Protein Allergy. J Pediatr Gastroenterol Nutr. 2020 04; 70(4):489-496.
    View in: PubMed
    Score: 0.009
  115. Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. J Interv Card Electrophysiol. 2000 Apr; 4(1):301-5.
    View in: PubMed
    Score: 0.009
  116. Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. J Comp Eff Res. 2020 04; 9(5):375-385.
    View in: PubMed
    Score: 0.009
  117. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020 04; 26(4):577-588.
    View in: PubMed
    Score: 0.009
  118. Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2000 Feb; 11(2):160-7.
    View in: PubMed
    Score: 0.009
  119. Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):21-4.
    View in: PubMed
    Score: 0.009
  120. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):25-9.
    View in: PubMed
    Score: 0.009
  121. Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
    View in: PubMed
    Score: 0.009
  122. Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac?Resynchronization Device Therapy. J Am Coll Cardiol. 2019 11 26; 74(21):2588-2603.
    View in: PubMed
    Score: 0.009
  123. Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Am J Cardiol. 1999 Sep 01; 84(5):555-7.
    View in: PubMed
    Score: 0.009
  124. Cardiac arrhythmia: current therapy. Hosp Pract (1995). 1999 Sep 01; 34(9):27-8, 31-2, 35-8 passim.
    View in: PubMed
    Score: 0.009
  125. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
    View in: PubMed
    Score: 0.009
  126. Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. J Am Coll Cardiol. 1999 Aug; 34(2):358-62.
    View in: PubMed
    Score: 0.009
  127. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. Am Heart J. 1999 Jul; 138(1 Pt 1):133-6.
    View in: PubMed
    Score: 0.009
  128. Plasticity of left ventricular function with cardiac resynchronization therapy. J Interv Card Electrophysiol. 2020 Mar; 57(2):289-294.
    View in: PubMed
    Score: 0.009
  129. Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm. 2019 12; 16(12):1758-1765.
    View in: PubMed
    Score: 0.009
  130. The effect of procainamide on T wave alternans. J Cardiovasc Electrophysiol. 1999 May; 10(5):649-54.
    View in: PubMed
    Score: 0.009
  131. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 04; 12(4):e006665.
    View in: PubMed
    Score: 0.009
  132. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999 Jan; 137(1):100-3.
    View in: PubMed
    Score: 0.008
  133. The effect of shock configuration and delivered energy on defibrillation impedance. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):165-8.
    View in: PubMed
    Score: 0.008
  134. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):179-82.
    View in: PubMed
    Score: 0.008
  135. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol. 1998 Dec; 2(4):345-9.
    View in: PubMed
    Score: 0.008
  136. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.008
  137. Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm. 2019 04; 16(4):581-587.
    View in: PubMed
    Score: 0.008
  138. Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
    View in: PubMed
    Score: 0.008
  139. The effect of delivered energy on defibrillation shock impedance. J Interv Card Electrophysiol. 1998 Sep; 2(3):273-7.
    View in: PubMed
    Score: 0.008
  140. Effect of heart rate on T wave alternans. J Cardiovasc Electrophysiol. 1998 Jul; 9(7):703-8.
    View in: PubMed
    Score: 0.008
  141. Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk?of Heart Failure. J Am Coll Cardiol. 2018 06 12; 71(23):2603-2611.
    View in: PubMed
    Score: 0.008
  142. Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
    View in: PubMed
    Score: 0.008
  143. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun; 36(6):778-92.
    View in: PubMed
    Score: 0.008
  144. Comparison of single- and dual-coil active pectoral defibrillation lead systems. J Am Coll Cardiol. 1998 May; 31(6):1391-4.
    View in: PubMed
    Score: 0.008
  145. Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Am Heart J. 2018 07; 201:160-163.
    View in: PubMed
    Score: 0.008
  146. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Apr; 9(4):350-4.
    View in: PubMed
    Score: 0.008
  147. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Mar; 9(3):240-4.
    View in: PubMed
    Score: 0.008
  148. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
    View in: PubMed
    Score: 0.008
  149. Implications and treatment of atrial fibrillation after cardiothoracic surgery. Curr Opin Cardiol. 1998 Jan; 13(1):20-7.
    View in: PubMed
    Score: 0.008
  150. Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. Polaris Investigator Group. Am J Cardiol. 1997 Dec 01; 80(11):1444-7.
    View in: PubMed
    Score: 0.008
  151. Strength-duration relationship for human transvenous defibrillation. Circulation. 1997 Nov 18; 96(10):3517-20.
    View in: PubMed
    Score: 0.008
  152. Lead system optimization for transvenous defibrillation. Am J Cardiol. 1997 Nov 01; 80(9):1163-7.
    View in: PubMed
    Score: 0.008
  153. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol. 1997 Oct 15; 80(8):1098-100.
    View in: PubMed
    Score: 0.008
  154. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.008
  155. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
    View in: PubMed
    Score: 0.008
  156. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
    View in: PubMed
    Score: 0.008
  157. Permanent pacing from the coronary sinus in a patient with an implantable defibrillator. Pacing Clin Electrophysiol. 1997 Sep; 20(9 Pt 1):2286-7.
    View in: PubMed
    Score: 0.008
  158. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997 Jul; 30(1):233-6.
    View in: PubMed
    Score: 0.008
  159. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
    View in: PubMed
    Score: 0.008
  160. Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. Pacing Clin Electrophysiol. 1997 Jun; 20(6):1682-5.
    View in: PubMed
    Score: 0.008
  161. Effect of waveform tilt on defibrillation thresholds in humans. J Cardiovasc Electrophysiol. 1997 May; 8(5):496-501.
    View in: PubMed
    Score: 0.008
  162. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May 01; 38(17):1339-1344.
    View in: PubMed
    Score: 0.008
  163. The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997 Mar 01; 79(5):679-81.
    View in: PubMed
    Score: 0.007
  164. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.007
  165. Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. Am J Cardiol. 1997 Feb 15; 79(4):502-5.
    View in: PubMed
    Score: 0.007
  166. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
    View in: PubMed
    Score: 0.007
  167. Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing Clin Electrophysiol. 1997 Jan; 20(1 Pt 2):208-11.
    View in: PubMed
    Score: 0.007
  168. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.007
  169. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996 Nov 01; 28(5):1278-82.
    View in: PubMed
    Score: 0.007
  170. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
    View in: PubMed
    Score: 0.007
  171. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
    View in: PubMed
    Score: 0.007
  172. Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
    View in: PubMed
    Score: 0.007
  173. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol. 1996 Sep 01; 78(5):540-3.
    View in: PubMed
    Score: 0.007
  174. Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
    View in: PubMed
    Score: 0.007
  175. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol. 1996 Aug 01; 78(3):313-6.
    View in: PubMed
    Score: 0.007
  176. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
    View in: PubMed
    Score: 0.007
  177. Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial. Pediatrics. 2016 06; 137(6).
    View in: PubMed
    Score: 0.007
  178. Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
    View in: PubMed
    Score: 0.007
  179. Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: a randomized controlled trial. Allergy. 2016 05; 71(5):701-10.
    View in: PubMed
    Score: 0.007
  180. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
    View in: PubMed
    Score: 0.007
  181. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr. 2016 Jan; 103(1):128-43.
    View in: PubMed
    Score: 0.007
  182. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-?B signalling. Nat Commun. 2015 Nov 03; 6:8777.
    View in: PubMed
    Score: 0.007
  183. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol. 1995 Oct; 26(4):967-73.
    View in: PubMed
    Score: 0.007
  184. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.007
  185. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.007
  186. Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
    View in: PubMed
    Score: 0.007
  187. Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol. 1995 Jun 01; 75(16):1158-61.
    View in: PubMed
    Score: 0.007
  188. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE?Study?and?EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28; 65(16):1605-1615.
    View in: PubMed
    Score: 0.007
  189. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
    View in: PubMed
    Score: 0.007
  190. The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
    View in: PubMed
    Score: 0.006
  191. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. Pacing Clin Electrophysiol. 1995 Mar; 18(3 Pt 1):478-81.
    View in: PubMed
    Score: 0.006
  192. Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events". Circulation. 2015 Feb 03; 131(5):e337-8.
    View in: PubMed
    Score: 0.006
  193. Overdrive pacing for atrial flutter. Am J Cardiol. 1994 Nov 15; 74(10):1021-3.
    View in: PubMed
    Score: 0.006
  194. Febrile seizures following measles and varicella vaccines in young children in Australia. Vaccine. 2015 Mar 10; 33(11):1412-7.
    View in: PubMed
    Score: 0.006
  195. Clinical epidemiology and predictors of outcome in children hospitalised with influenza A(H1N1)pdm09 in 2009: a prospective national study. Influenza Other Respir Viruses. 2014 Nov; 8(6):636-45.
    View in: PubMed
    Score: 0.006
  196. Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
    View in: PubMed
    Score: 0.006
  197. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 May 27; 129(21):2094-9.
    View in: PubMed
    Score: 0.006
  198. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994 Mar 01; 23(3):560-4.
    View in: PubMed
    Score: 0.006
  199. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.006
  200. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
    View in: PubMed
    Score: 0.006
  201. Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
    View in: PubMed
    Score: 0.006
  202. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.006
  203. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol. 2013 Jun 01; 12(6):619-25.
    View in: PubMed
    Score: 0.006
  204. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
    View in: PubMed
    Score: 0.006
  205. The invasion inhibitor sarasinoside A1 reverses mesenchymal tumor transformation in an E-cadherin-independent manner. Mol Cancer Res. 2013 May; 11(5):530-40.
    View in: PubMed
    Score: 0.006
  206. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013 Apr; 39(4):551-8.
    View in: PubMed
    Score: 0.006
  207. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013 Apr; 24(4):381-7.
    View in: PubMed
    Score: 0.006
  208. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
    View in: PubMed
    Score: 0.005
  209. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
    View in: PubMed
    Score: 0.005
  210. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
    View in: PubMed
    Score: 0.005
  211. Palliative care for patients with chronic obstructive pulmonary disease: exploring the landscape. Intern Med J. 2012 Sep; 42(9):1053-7.
    View in: PubMed
    Score: 0.005
  212. Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. Heart Rhythm. 2012 Oct; 9(10):1667-73.
    View in: PubMed
    Score: 0.005
  213. Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Aug 01; 5(4):626-31.
    View in: PubMed
    Score: 0.005
  214. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
    View in: PubMed
    Score: 0.005
  215. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12; 366(2):120-9.
    View in: PubMed
    Score: 0.005
  216. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
    View in: PubMed
    Score: 0.005
  217. Acute clinical evaluation of a left ventricular automatic threshold determination algorithm based on evoked response sensing. Pacing Clin Electrophysiol. 2012 Mar; 35(3):348-56.
    View in: PubMed
    Score: 0.005
  218. Esmolol and ventilatory function in cardiac patients with COPD. Chest. 1991 Nov; 100(5):1215-8.
    View in: PubMed
    Score: 0.005
  219. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage. 2013 Jul 15; 75:249-261.
    View in: PubMed
    Score: 0.005
  220. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.005
  221. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage. 2013 Nov 01; 81:484-495.
    View in: PubMed
    Score: 0.005
  222. Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old. Vaccine. 2011 Jun 06; 29(25):4230-7.
    View in: PubMed
    Score: 0.005
  223. Intraoperative anaphylaxis: an association with latex sensitivity. J Allergy Clin Immunol. 1991 Mar; 87(3):662-6.
    View in: PubMed
    Score: 0.005
  224. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.005
  225. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.005
  226. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.005
  227. Intraoperative anaphylaxis to latex. Can J Anaesth. 1990 Jul; 37(5):589-92.
    View in: PubMed
    Score: 0.005
  228. A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
    View in: PubMed
    Score: 0.005
  229. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
    View in: PubMed
    Score: 0.004
  230. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.004
  231. Adverse events arising from a palliative care survey. Palliat Med. 2009 Oct; 23(7):665-9.
    View in: PubMed
    Score: 0.004
  232. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009 Jul-Aug; 25(6):469-76.
    View in: PubMed
    Score: 0.004
  233. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
    View in: PubMed
    Score: 0.004
  234. Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
    View in: PubMed
    Score: 0.004
  235. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
    View in: PubMed
    Score: 0.004
  236. Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J. 2007 Jun; 153(6):951-9.
    View in: PubMed
    Score: 0.004
  237. Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
    View in: PubMed
    Score: 0.003
  238. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
    View in: PubMed
    Score: 0.003
  239. Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies. Am J Cardiol. 2004 Dec 15; 94(12):1572-4.
    View in: PubMed
    Score: 0.003
  240. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64.
    View in: PubMed
    Score: 0.003
  241. Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
    View in: PubMed
    Score: 0.003
  242. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol. 2003 Sep 17; 42(6):1098-102.
    View in: PubMed
    Score: 0.003
  243. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20; 42(4):627-33.
    View in: PubMed
    Score: 0.003
  244. Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
    View in: PubMed
    Score: 0.003
  245. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
    View in: PubMed
    Score: 0.003
  246. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
    View in: PubMed
    Score: 0.003
  247. National study of adverse reactions after vaccination with bacille Calmette-Gu?rin. Clin Infect Dis. 2002 Feb 15; 34(4):447-53.
    View in: PubMed
    Score: 0.003
  248. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.002
  249. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
    View in: PubMed
    Score: 0.002
  250. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001 Jan; 141(1):92-8.
    View in: PubMed
    Score: 0.002
  251. Assessing the efficacy of a school-based asthma education program for children: a pilot study. Can J Public Health. 2001 Jan-Feb; 92(1):30-4.
    View in: PubMed
    Score: 0.002
  252. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29; 342(26):1937-45.
    View in: PubMed
    Score: 0.002
  253. No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May; 47(5):687.
    View in: PubMed
    Score: 0.002
  254. Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease. Neurosci Lett. 2000 Feb 25; 280(3):215-9.
    View in: PubMed
    Score: 0.002
  255. Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15; 88(5):465-8.
    View in: PubMed
    Score: 0.002
  256. Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures. Anesth Analg. 1999 Oct; 89(4):893-8.
    View in: PubMed
    Score: 0.002
  257. Hemostatic responses to maximal exercise in oral contraceptive users. Am J Obstet Gynecol. 1999 Oct; 181(4):958-63.
    View in: PubMed
    Score: 0.002
  258. The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 06; 270(3):133-6.
    View in: PubMed
    Score: 0.002
  259. No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. Neurosci Lett. 1999 May 14; 266(3):193-6.
    View in: PubMed
    Score: 0.002
  260. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation. 1999 Apr 13; 99(14):1843-50.
    View in: PubMed
    Score: 0.002
  261. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14; 252(2):95-8.
    View in: PubMed
    Score: 0.002
  262. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998 Jun 19; 249(2-3):115-8.
    View in: PubMed
    Score: 0.002
  263. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate. J Allergy Clin Immunol. 1998 Mar; 101(3):425-6.
    View in: PubMed
    Score: 0.002
  264. Refusal of out-of-hospital medical care: effect of medical-control physician assertiveness on transport rate. Acad Emerg Med. 1998 Jan; 5(1):4-8.
    View in: PubMed
    Score: 0.002
  265. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol. 1997 Nov 01; 80(9):1183-7.
    View in: PubMed
    Score: 0.002
  266. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997; 14(3):299-305.
    View in: PubMed
    Score: 0.002
  267. Use of care and subsequent mortality: the importance of gender. Health Serv Res. 1996 Aug; 31(3):347-63.
    View in: PubMed
    Score: 0.002
  268. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1996 Feb; 97(2):588-95.
    View in: PubMed
    Score: 0.002
  269. Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. Am Heart J. 1995 Sep; 130(3 Pt 1):489-93.
    View in: PubMed
    Score: 0.002
  270. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
    View in: PubMed
    Score: 0.002
  271. Acute hemodynamic effects of atrio-biventricular pacing in humans. Ann Thorac Surg. 1995 Feb; 59(2):294-300.
    View in: PubMed
    Score: 0.002
  272. A home-based geriatric assessment, follow-up and health promotion program: design, methods, and baseline findings from a 3-year randomized clinical trial. Aging (Milano). 1994 Apr; 6(2):105-20.
    View in: PubMed
    Score: 0.002
  273. Health insurance and subjective health status: data from the 1987 National Medical Expenditure survey. Am J Public Health. 1993 Sep; 83(9):1295-9.
    View in: PubMed
    Score: 0.001
  274. Racial differentials in the identification of hypercholesterolemia. J Fam Pract. 1993 Apr; 36(4):425-30.
    View in: PubMed
    Score: 0.001
  275. Delinquency as defense. Am J Orthopsychiatry. 1972 Apr; 42(3):463-79.
    View in: PubMed
    Score: 0.001
  276. Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias. Ann Intern Med. 1992 Mar 01; 116(5):382-7.
    View in: PubMed
    Score: 0.001
  277. Hypomagnesemia is a frequent finding in the emergency department in patients with chest pain. Arch Intern Med. 1991 Nov; 151(11):2185-90.
    View in: PubMed
    Score: 0.001
  278. Barriers to cholesterol testing in a rural community. J Fam Pract. 1991 Jun; 32(6):614-8.
    View in: PubMed
    Score: 0.001
  279. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. Proc Natl Acad Sci U S A. 1991 May 15; 88(10):4148-52.
    View in: PubMed
    Score: 0.001
  280. Demonstration of an internal pancreatic fistula by computed tomography. Gastrointest Radiol. 1984; 9(2):123-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.